Panretin and Verteporfin
Determining the interaction of Panretin and Verteporfin and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort). MANAGEMENT: Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Multum Information Services, Inc. Expert Review Panel" "Product Information. Visudyne (verteporfin)" Valeant Pharmaceuticals, Costa Mesa, CA.
Professional:MONITOR: Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort).
MANAGEMENT: Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Multum Information Services, Inc. Expert Review Panel"
- "Product Information. Visudyne (verteporfin)" Valeant Pharmaceuticals, Costa Mesa, CA.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Panretin-Verteporfin Intravenous, Injection
- Panretin-Verzenio
- Panretin-Vesanoid
- Panretin-VESIcare
- Panretin-Vestura
- Panretin-Vet One Silver Nitrate
- Verteporfin-Panretin Topical
- Verteporfin-Pantopon Oral
- Verteporfin-Pantoprazole
- Verteporfin-Pantoprazole Delayed-Release Granules
- Verteporfin-Pantoprazole Delayed-Release Tablets
- Verteporfin-Pantoprazole Injection